For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | - | - | - | 0 |
| Research and development | 3,000 | -3,000 | 8,000 | 14,000 |
| General and administrative | 1,289,000 | 911,000 | 858,000 | 1,534,000 |
| Loss on mannkind transaction | - | - | - | 0 |
| Total operating expenses | 1,292,000 | 908,000 | 866,000 | 1,548,000 |
| Loss from operations | -1,292,000 | -908,000 | -866,000 | -1,548,000 |
| Interest income | 12,000 | 53,500* | 30,000 | 41,000 |
| Fair value adjustment of warrants | - | 33,500* | - | -1,000 |
| Other income (expense), net | 108,000 | -40,000 | -41,000 | -43,000 |
| Total other income (expense), net | 120,000 | -20,000 | -11,000 | -1,000 |
| Net loss | -1,172,000 | -928,000 | -877,000 | -1,549,000 |
| Basic EPS | -0.32 | -0.254 | -0.24 | -0.42 |
| Diluted EPS | -0.32 | -0.254 | -0.24 | -0.42 |
| Basic Average Shares | 3,652,285 | 3,652,285 | 3,652,285 | 3,652,285 |
| Diluted Average Shares | 3,652,285 | 3,652,285 | 3,652,285 | 3,652,285 |
Pulmatrix, Inc. (PULM)
Pulmatrix, Inc. (PULM)